According to Future Market Insights (FMI) analysis in a recent market survey, the global clinical research organization market was valued at US$ 58.0 Billion in 2022 and is expected to reach US$ 139.6 Billion by 2033.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 58.02 Billion |
| Market Value 2023 | US$ 62.43 Billion |
| Market Value 2033 | US$ 139.56 Billion |
| CAGR 2023 to 2033 | 8.4% |
| Share of Top 5 Countries | 63.4% |
| Key Players | The key players in the market are Charles River Laboratories, Laboratory Corporation of America Holdings, IQVIA Inc, Parexel International Corporation, ICON plc., Medpace, Syneos Health, CTI Clinical Trial and Consulting Services, Neuroservices Alliance, QPS Neuropharmacology, MD Biosciences, EphyX Neuroscience. |
The Clinical Research Organization (CRO) market refers to the industry segment companies and organizations providing clinical research services to pharmaceutical, biotechnology, and medical device companies. It encompasses the commercial activities and financial transactions associated with outsourcing clinical trials and research studies.
The market is driven by the increasing demand for efficient and cost-effective drug development processes. Pharmaceutical and biotech companies often outsource clinical research activities to CROs to leverage their specialized expertise, infrastructure, and resources. This allows the companies to focus on their core competencies, such as drug discovery and marketing, while relying on CROs for the execution of clinical trials.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the market grew at a CAGR of 6.4% between 2018 to 2022.
With a historical forecast of stable growth, the clinical research organization (CRO) industry has seen significant growth in recent years. The rise in demand for outsourced clinical trials from pharmaceutical, biotechnology, and medical device businesses is what is causing this surge.
The clinical research organization (CRO) market is anticipated to maintain its growth trajectory in the upcoming years, according to the projection. The expansion of the CRO market is anticipated to be fueled by an increase in clinical trials, a rise in the need for personalized medication, and the prevalence of chronic diseases. Various clinical trial processes, including patient recruiting and retention, data analysis, and medication discovery, are using these technologies.
Considering this, FMI expects the global clinical research organization market to grow at a CAGR of 8.4% through the forecasted years.
CROs can provide specialized services for carrying out clinical studies in this field as personalized medicine and targeted medicines gain popularity. This covers the identification of biomarkers, patient screening, and customized trial planning. CROs now have more potential due to the use of real-world data and virtual trials.
Companies with expertise in these fields can provide pharma/biotech firms with specialized services and assistance for real-world research as well as for virtual studies, which can shorten the trial duration and expense. It can also include telemedicine and digital health technology in clinical trials to raise study compliance, increase patient participation, and offer ongoing monitoring. CROs can be assisted in adopting these technologies and incorporating them into clinical trial designs by businesses offering specialised services.
They are now also able to provide specialized services in data analytics and machine learning due to the increased availability of real-time data in clinical trials. To do this, one can employ predictive analytics to foresee dangers, spot trends, and improve study design, which thereby helps in the growth of the global market.
Principal Consultant
Ensuring compliance with regulatory regulations is one of the biggest issues for CRO businesses. Navigating through each nation's unique legislation can be time-consuming and expensive. To make sure that all applicable regulations are followed, CROs must have a strong regulatory staff. Companies in the pharma and biotech industries are increasingly looking for CROs that can offer services at a low cost without sacrificing quality or timeliness. To remain competitive, CROs may need to modify their pricing strategies and business models in response to margin concerns.
Large-scale multicenter trials might be difficult to finance since there is sometimes a lack of funding for clinical trials. To maximize the cost-effectiveness of clinical studies, sponsors, researchers, and CROs must collaborate due to the high cost of drug development and growing cost constraints. The capabilities of CROs may also be constrained by a lack of highly skilled workers, including researchers, data administrators, and statisticians. Lack of qualified personnel may cause inefficiencies, delays in hiring and retaining staff, and a general decline in the quality of project outputs.
The USA clinical research organization market is expected to register 32.0% in the global market in 2022.
There are several life science businesses in the United States, and these businesses are embracing innovations in clinical research. CROs that offer these services are in demand as technological innovations like telemedicine and virtual trials are used more frequently. Drug development efforts by biotech and pharmaceutical firms are increasing in the USA These businesses are turning more and more to CROs for assistance, including access to facilities and programs for current patients, enrollment and recruiting information, personalized protocol design, higher trial completion rates, and lower costs.
China accounted for around 9.3% market share in 2022 globally.
The clinical research organization (CRO) market in China is expanding due to several factors. The rapidly ageing and expanding Chinese population is a significant contributing element, which has raised demand for cutting-edge medical cures and treatments. Furthermore, recent reforms and laws adopted by the Chinese government have made it simpler to conduct clinical trials and research there.
The government has put in place many steps to hasten the regulatory approval procedure for novel pharmaceuticals and therapies, luring multinational companies to locate their research and development operations in the nation. Additionally, the development of healthcare and rising income levels in China have raised the demand for advanced healthcare services, such as clinical research and triage.
India holds a 7.4% value share in the global market in 2022.
The clinical research organization (CRO) market is expanding in India for a variety of reasons. Large and diversified patient populations are a significant contributing element, which makes India a desirable location for carrying out clinical studies. Due to the country's accessible healthcare services and cheaper cost of living, clinical trials in India are also more economical than in many other nations.
The supportive regulatory environment created by the Indian government, which promotes clinical research activities by streamlining the approval procedure for clinical trials and cutting the time needed to secure regulatory approvals, is another important aspect. More foreign money has also been invested in India's clinical research sector as a result of the rise in medical tourism there.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The post-approval services segment held the major chunk of about 45.7% of the global market by the end of 2022.
A key factor in the expansion of the clinical research organization (CRO) market is post-approval services. Post-approval services are the actions taken after regulatory bodies or authorities have given their clearance for the use of a product or therapy. These services are essential for maintaining the product's safety and effectiveness as well as for carrying out additional studies that could increase the product or therapy's effectiveness.
In order to diversify their service portfolio and give their clients value-added services, several CROs offer post-approval services. Pharmacovigilance, medical monitoring, safety monitoring, data management, statistical analysis, quality assurance, and regulatory compliance are a few examples of the services that may be provided.
The In-house production segment contribute 58.3% share of the global market in 2022.
The term in-house describes a method of conducting all phases of clinical research within a single organization, often comprising study design, data management, monitoring, and statistical analysis. Clinical research organizations (CRO) market development is still mostly fueled by internal clinical research conducted by pharmaceutical and biotech corporations. The in-house methodology has several benefits, including more control over studies, quicker decision-making, and reduced reliance on outside suppliers.
A pharmaceutical or biotech company's ability to quickly and efficiently react to any noteworthy events or changes in the study protocol can be facilitated by in-house clinical research, which provides better control over study data and technological competence.
The oncology by indication segment accounted for a revenue share of 23.4% in the global market at the end of 2022.
One of the markets for clinical research organizations (CROs) that is expanding the quickest is oncology, which has had a big impact on the development of the sector. Cancer research is an appealing subject for CROs to concentrate their attention on because it is a complex and fast-developing field of medicine that calls for a high degree of knowledge and resources.
Many variables, such as the rising cancer burden globally, developments in molecular biology and genomics, and the creation of more advanced and novel immuno-oncology medicines, all contribute to the expansion of oncology research and the CRO business. The need for more advanced oncology therapies that can address patients' complicated requirements is growing as cancer rates are expected to keep rising.
The pharmaceutical and biotechnology companies hold a share of 45.6% of the global market in 2022.
The market for clinical research organizations (CROs) is expanding mostly due to the efforts of the pharmaceutical and biotechnology industries. These businesses invest a lot of money in the discovery of novel treatments and medications, and they frequently contract out some or all of the clinical research work to CROs to increase productivity and access to funding.
A great deal of financing for clinical research studies-particularly those involving new medicinal compounds-comes from pharmaceutical and biotech corporations. These businesses frequently look to collaborate with CROs who can offer specialized knowledge in research design, data administration, and general project management. Pharmaceutical and biotech companies can shorten the time it takes to develop new drugs by outsourcing clinical trial efforts to CROs and concentrating internal resources on core research and development tasks.
The market's key vendors are concentrating on diversifying their product offerings to strengthen their market share in clinical research organizations and to broaden their presence in developing nations. Pricing strategies, market strategies, technology improvements, regulatory compliance, and acquisition and distribution agreements with other companies to extend their business are the main tactics used by manufacturers to acquire a competitive edge in the market.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the clinical research organization market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East; and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, Nordics, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Australia, New Zealand, Türkiye, South Africa, North Africa, and GCC Countries |
| Key Segments Covered | Service, Production, Indication, End User, and Region |
| Key Companies Profiled | Charles River Laboratories; Laboratory Corporation of America Holdings; IQVIA Inc; Parexel International Corporation; ICON plc.; Medpace, Syneos Health; CTI Clinical Trial and Consulting Services; Neuroservices Alliance; QPS Neuropharmacology; MD Biosciences; EphyX Neuroscience |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The clinical research organization market is slated to attain US$ 62.43 billion in 2023.
The market is expected to attain a value of US$ 139.56 billion by 2033.
Increasing popularity of targeted medicines and personalized medicines are creating opportunities for key players.
Strict regulatory regulations and lack of funding for clinical trials are pulling back the market’s growth.
IQVIA Inc, Parexel International Corporation, and ICON plc. are the key players in the CRO industry.
1. Global Market- Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusion and Exclusion 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Service Innovation / Development Trends 4. Value-Added Insights 4.1. Service Adoption/Usage Analysis, By Region 4.2. Clinical Trials Analysis 4.3. Regulatory Scenario 4.4. Porters Analysis 4.5. PESTLE Analysis 4.6. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Market Outlook 5.1.3. Research and Development Expenditure Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Strategic Developments by Key Players 5.2.2. Technological Advancements 5.2.3. Top Companies Historical Growth 5.2.4. Research and Development Activities 5.2.5. Increasing Number of Clinical Research Organizations 5.2.6. Cost of Services 5.2.7. Increasing Prevalence of Targeted Diseases 5.2.8. Growing number of CROs 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Service 6.1.2. Revenue By Production 6.1.3. Revenue By Indication 6.1.4. Revenue By End User 6.1.5. Revenue By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Service 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis by Service, 2018 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Service, 2023 to 2033 8.3.1. Drug Discovery Services 8.3.2. Pre-clinical Services 8.3.3. Clinical Services 8.3.4. Post Approval Services 8.4. Market Attractiveness Analysis by Service 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Production 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis by Production, 2018 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Production, 2023 to 2033 9.3.1. In-house 9.3.2. Outsourced 9.4. Market Attractiveness Analysis by Production 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Indication, 2018 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 10.3.1. Oncology 10.3.2. CNS 10.3.3. Cardiovascular Diseases 10.3.4. Metabolic Disorders 10.3.5. Immunology 10.3.6. Respiratory 10.3.7. Musculoskeletal Disorders 10.3.8. Hematological Disorders 10.3.9. Others 10.4. Market Attractiveness Analysis By Indication 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By End User, 2018 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 11.3.1. Pharmaceutical & Biotechnology Companies 11.3.2. Medical Device Companies 11.3.3. Governments & Private Firms 11.3.4. Academic Institutions 11.3.5. Others 11.4. Market Attractiveness Analysis By End User 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis by Region, 2018 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. South Asia 12.3.5. East Asia 12.3.6. Oceania 12.3.7. Middle East & Africa(MEA) 12.4. Market Attractiveness Analysis by Region 13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. USA 13.3.1.2. Canada 13.3.2. By Service 13.3.3. By Production 13.3.4. By Indication 13.3.5. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Service 13.4.3. By Production 13.4.4. By Indication 13.4.5. By End User 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country-Level Analysis & Forecast 13.8.1. USA Market 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Service 13.8.1.2.2. By Production 13.8.1.2.3. By Indication 13.8.1.2.4. By End User 13.8.2. Canada Market 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Service 13.8.2.2.2. By Production 13.8.2.2.3. By Indication 13.8.2.2.4. By End User 14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast Recast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Service 14.3.3. By Production 14.3.4. By Indication 14.3.5. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Service 14.4.3. By Production 14.4.4. By Indication 14.4.5. By End User 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country-Level Analysis & Forecast 14.8.1. Brazil Market 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Service 14.8.1.2.2. By Production 14.8.1.2.3. By Indication 14.8.1.2.4. By End User 14.8.2. Mexico Market 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Service 14.8.2.2.2. By Production 14.8.2.2.3. By Indication 14.8.2.2.4. By End User 14.8.3. Argentina Market 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Service 14.8.3.2.2. By Production 14.8.3.2.3. By Indication 14.8.3.2.4. By End User 15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. UK 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Nordic Countries 15.3.1.8. Russia 15.3.1.9. Rest of Europe 15.3.2. By Service 15.3.3. By Production 15.3.4. By Indication 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Service 15.4.3. By Production 15.4.4. By Indication 15.4.5. By End User 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country-Level Analysis & Forecast 15.8.1. Germany Market 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Service 15.8.1.2.2. By Production 15.8.1.2.3. By Indication 15.8.1.2.4. By End User 15.8.2. Italy Market 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Service 15.8.2.2.2. By Production 15.8.2.2.3. By Indication 15.8.2.2.4. By End User 15.8.3. France Market 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Service 15.8.3.2.2. By Production 15.8.3.2.3. By Indication 15.8.3.2.4. By End User 15.8.4. UK Market 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Service 15.8.4.2.2. By Production 15.8.4.2.3. By Indication 15.8.4.2.4. By End User 15.8.5. Spain Market 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast by Market Taxonomy 15.8.5.2.1. By Service 15.8.5.2.2. By Production 15.8.5.2.3. By Indication 15.8.5.2.4. By End User 15.8.6. BENELUX Market 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast by Market Taxonomy 15.8.6.2.1. By Service 15.8.6.2.2. By Production 15.8.6.2.3. By Indication 15.8.6.2.4. By End User 15.8.7. Nordic Countries Market 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast by Market Taxonomy 15.8.7.2.1. By Service 15.8.7.2.2. By Production 15.8.7.2.3. By Indication 15.8.7.2.4. By End User 15.8.8. Russia Market 15.8.8.1. Introduction 15.8.8.2. Market Analysis and Forecast by Market Taxonomy 15.8.8.2.1. By Service 15.8.8.2.2. By Production 15.8.8.2.3. By Indication 15.8.8.2.4. By End User 16. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Philippines 16.3.1.6. Vietnam 16.3.1.7. Rest of South Asia 16.3.2. By Service 16.3.3. By Production 16.3.4. By Indication 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Service 16.4.3. By Production 16.4.4. By Indication 16.4.5. By End User 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country-Level Analysis & Forecast 16.8.1. India Market 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Service 16.8.1.2.2. By Production 16.8.1.2.3. By Indication 16.8.1.2.4. By End User 16.8.2. Thailand Market 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Service 16.8.2.2.2. By Production 16.8.2.2.3. By Indication 16.8.2.2.4. By End User 16.8.3. Indonesia Market 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Service 16.8.3.2.2. By Production 16.8.3.2.3. By Indication 16.8.3.2.4. By End User 16.8.4. Malaysia Market 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Service 16.8.4.2.2. By Production 16.8.4.2.3. By Indication 16.8.4.2.4. By End User 16.8.5. Philippines Market 16.8.5.1. Introduction 16.8.5.2. Market Analysis and Forecast by Market Taxonomy 16.8.5.2.1. By Service 16.8.5.2.2. By Production 16.8.5.2.3. By Indication 16.8.5.2.4. By End User 16.8.6. Vietnam Market 16.8.6.1. Introduction 16.8.6.2. Market Analysis and Forecast by Market Taxonomy 16.8.6.2.1. By Service 16.8.6.2.2. By Production 16.8.6.2.3. By Indication 16.8.6.2.4. By End User 17. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Service 17.3.3. By Production 17.3.4. By Indication 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Service 17.4.3. By Production 17.4.4. By Indication 17.4.5. By End User 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country-Level Analysis & Forecast 17.8.1. China Market 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Service 17.8.1.2.2. By Production 17.8.1.2.3. By Indication 17.8.1.2.4. By End User 17.8.2. Japan Market 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Service 17.8.2.2.2. By Production 17.8.2.2.3. By Indication 17.8.2.2.4. By End User 17.8.3. South Korea Market 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Service 17.8.3.2.2. By Production 17.8.3.2.3. By Indication 17.8.3.2.4. By End User 18. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Service 18.3.3. By Production 18.3.4. By Indication 18.3.5. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Service 18.4.3. By Production 18.4.4. By Indication 18.4.5. By End User 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country-Level Analysis & Forecast 18.8.1. Australia Market 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Service 18.8.1.2.2. By Production 18.8.1.2.3. By Indication 18.8.1.2.4. By End User 18.8.2. New Zealand Market 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Service 18.8.2.2.2. By Production 18.8.2.2.3. By Indication 18.8.2.2.4. By End User 19. Middle East & Africa Market Analysis 2018 to 2022and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. South Africa 19.3.1.4. North Africa 19.3.1.5. Rest of MEA 19.3.2. By Service 19.3.3. By Production 19.3.4. By Indication 19.3.5. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Service 19.4.3. By Production 19.4.4. By Indication 19.4.5. By End User 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country-Level Analysis & Forecast 19.8.1. GCC Countries Market 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Service 19.8.1.2.2. By Production 19.8.1.2.3. By Indication 19.8.1.2.4. By End User 19.8.2. Türkiye Market 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Service 19.8.2.2.2. By Production 19.8.2.2.3. By Indication 19.8.2.2.4. By End User 19.8.3. South Africa Market 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Service 19.8.3.2.2. By Production 19.8.3.2.3. By Indication 19.8.3.2.4. By End User 19.8.4. North Africa Market 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Service 19.8.4.2.2. By Production 19.8.4.2.3. By Indication 19.8.4.2.4. By End User 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Charles River Laboratories 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Key Financial 20.3.1.4. Sales Footprint 20.3.1.5. SWOT Analysis 20.3.1.6. Key Developments 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategies 20.3.1.7.2. Product Strategies 20.3.1.7.3. Channel Strategies 20.3.2. Laboratory Corporation of America Holdings 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Key Financial 20.3.2.4. Sales Footprint 20.3.2.5. SWOT Analysis 20.3.2.6. Key Developments 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategies 20.3.2.7.2. Product Strategies 20.3.2.7.3. Channel Strategies 20.3.3. IQVIA Inc 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Key Financial 20.3.3.4. Sales Footprint 20.3.3.5. SWOT Analysis 20.3.3.6. Key Developments 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategies 20.3.3.7.2. Product Strategies 20.3.3.7.3. Channel Strategies 20.3.4. Parexel International Corporation 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Key Financial 20.3.4.4. Sales Footprint 20.3.4.5. SWOT Analysis 20.3.4.6. Key Developments 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategies 20.3.4.7.2. Product Strategies 20.3.4.7.3. Channel Strategies 20.3.5. ICON plc. 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Key Financial 20.3.5.4. Sales Footprint 20.3.5.5. SWOT Analysis 20.3.5.6. Key Developments 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategies 20.3.5.7.2. Product Strategies 20.3.5.7.3. Channel Strategies 20.3.6. Medpace, Syneos Health 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Key Financial 20.3.6.4. Sales Footprint 20.3.6.5. SWOT Analysis 20.3.6.6. Key Developments 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategies 20.3.6.7.2. Product Strategies 20.3.6.7.3. Channel Strategies 20.3.7. CTI Clinical Trial and Consulting Services 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Key Financial 20.3.7.4. Sales Footprint 20.3.7.5. SWOT Analysis 20.3.7.6. Key Developments 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategies 20.3.7.7.2. Product Strategies 20.3.7.7.3. Channel Strategies 20.3.8. Neuro Services Alliance 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Key Financial 20.3.8.4. Sales Footprint 20.3.8.5. SWOT Analysis 20.3.8.6. Key Developments 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategies 20.3.8.7.2. Product Strategies 20.3.8.7.3. Channel Strategies 20.3.9. QPS Neuropharmacology 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Key Financial 20.3.9.4. Sales Footprint 20.3.9.5. SWOT Analysis 20.3.9.6. Key Developments 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategies 20.3.9.7.2. Product Strategies 20.3.9.7.3. Channel Strategies 20.3.10. MD Biosciences 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Key Financial 20.3.10.4. Sales Footprint 20.3.10.5. SWOT Analysis 20.3.10.6. Key Developments 20.3.10.7. Strategy Overview 20.3.10.7.1. Marketing Strategies 20.3.10.7.2. Product Strategies 20.3.10.7.3. Channel Strategies 20.3.11. EphyX Neuroscience. 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Key Financial 20.3.11.4. Sales Footprint 20.3.11.5. SWOT Analysis 20.3.11.6. Key Developments 20.3.11.7. Strategy Overview 20.3.11.7.1. Marketing Strategies 20.3.11.7.2. Product Strategies 20.3.11.7.3. Channel Strategies 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Clinical Research Organization Market
